Dr. Vishy Chaudhary, MD

Dr. Chaudhary practices at Rockefeller Neuroscience Institute - Neurology - HOPD in Morgantown, West Virginia.

Dr. Chaudhary's NPI, 1740501154, was assigned on June 21, 2010. Dr. Chaudhary holds West Virginia license 28838.

Dr. Chaudhary's primary practice is Rockefeller Neuroscience Institute - Neurology - HOPD, at 33 Medical Center Dr, Morgantown, WV 26505.

Dr. Chaudhary's primary practice is Rockefeller Neuroscience Institute - Neurology - HOPD in Morgantown, West Virginia. Dr. Chaudhary is also affiliated with J.W. Ruby Memorial Hospital. The medical group on file is University of Pittsburgh Physicians, Department of Radiology. Dmand AI also links Dr. Chaudhary to 5 more hospitals, 7 medical groups, 1 physician office, 1 group practice or clinic and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chaudhary practices, 10 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Chaudhary's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dmand AI has Dr. Chaudhary's licenses on file in 4 states: West Virginia, Minnesota, Pennsylvania and Texas.

CMS data shows 259 Medicare services from Dr. Chaudhary across 6 procedure codes in 2024, for 156 Medicare patients. Medicare paid $21,001 for them.

CMS counts 156 Medicare patients who saw Dr. Chaudhary in 2024. The largest group is under 65, with 64 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 29% are also on Medicaid. Their average risk score is 4.71, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chaudhary's median patient age at 62, with 43% women.

In 2024, Dr. Chaudhary wrote 611 Medicare Part D claims for 74 patients. 92% of them were for generic drugs. CMS names the drug for 457 of them, across 20 drugs with 11 or more claims each, at $8,873 in total drug cost. In 2023, CMS named 197 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Chaudhary for performance year 2024, reported through an alternative payment model (APM). Dr. Chaudhary accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 22 papers to Dr. Chaudhary, published from 2016 to 2025. 2020 was the busiest year, with 4. The most frequent topics are Mycorrhizae, Symbiosis and Ecosystem. Dr. Chaudhary has published most often in New Phytol. Dr. Chaudhary's most frequent co-authors are Faryal Gul Afridi and Amit Kumar, MD.

CMS Open Payments shows 7 general payments to Dr. Chaudhary from 5 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Veloxis Pharmaceuticals, Inc. paid the most, $147.